0.017196
0.000000
0.000000
0.000000
0.017190
0.000000
0.000000
0.000000
0.018249
0.00000
0.00000
0.00000
Whittingham, J.L.
Zhang, Y.
Zakova, L.
Dodson, E.J.
Turkenburg, J.P.
Brange, J.
Dodson, G.G.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
16
90.00
90.00
90.00
58.152
58.174
54.797
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
O4 S -2
96.063
SULFATE ION
non-polymer
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
DK
Acta Crystallogr.,Sect.D
ABCRE6
0766
0907-4449
62
505
10.1107/S0907444906006871
16627943
I222 Crystal Form of Despentapeptide (B26-B30) Insulin Provides New Insights Into the Properties of Monomeric Insulin.
2006
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
120.0
1
IMAGE PLATE
2002-02-01
MARRESEARCH
SINGLE WAVELENGTH
M
x-ray
1
0.93300
1.0
ID14-2
ESRF
0.93300
SYNCHROTRON
ESRF BEAMLINE ID14-2
2383.698
INSULIN
2
man
polymer
2842.277
INSULIN
2
man
polymer
96.063
SULFATE ION
3
syn
non-polymer
18.015
water
65
nat
water
DESPENTAPEPTIDE-B26-B30 INSULIN
DESPENTAPEPTIDE-B26-B30 INSULIN
no
no
GIVEQCCTSICSLYQLENYCN
GIVEQCCTSICSLYQLENYCN
A,C
polypeptide(L)
no
no
FVNQHLCGSHLVEALYLVCGERGFF
FVNQHLCGSHLVEALYLVCGERGFF
B,D
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
HUMAN
sample
9606
HOMO SAPIENS
4932
SACCHAROMYCES CEREVISIAE
HUMAN
sample
9606
HOMO SAPIENS
4932
SACCHAROMYCES CEREVISIAE
1
2.2
45
2.00
20 % ACETIC ACID, 0.05 M SODIUM SULPHATE, PH 2
repository
Initial release
Version format compliance
Version format compliance
1
0
2006-03-03
1
1
2011-05-08
1
2
2011-07-13
INSULIN MUTANT B16 GLU, B24 GLY, DES-B30 , NMR, 20 STRUCTURES
R6 HUMAN INSULIN HEXAMER (NON-SYMMETRIC), NMR, 10 STRUCTURES
R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 10 STRUCTURES
HUMAN INSULIN MUTANT SERB9GLU
INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE
AN ACTIVE MINI-PROINSULIN, M2PI
STRUCTURE OF THE RHOMBOHEDRAL FORM OF THE M-CRESOL/INSULIN R6 HEXAMER
STRUCTURE OF THE MONOCLINIC FORM OF THE M -CRESOL/INSULIN R6 HEXAMER
THE STRUCTURE OF THE RESORCINOL/INSULIN R6 HEXAMER
FIRST PROTEIN STRUCTURE DETERMINED FROM X- RAY POWDERDIFFRACTION DATA
FIRST PROTEIN STRUCTURE DETERMINED FROM X- RAY POWDERDIFFRACTION DATA
1.2 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K
1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K
INSULIN AT PH 2: STRUCTURAL ANALYSIS OF THE CONDITIONS PROMOTING INSULIN FIBRE FORMATION.
INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY SER (F24S) (NMR, REPRESENTATIVE PLUS 9 STRUCTURES)
INSULIN (HUMAN, DES-PENTAPEPTIDE (B 26 - B 30)) (NMR, REPRESENTATIVE PLUS 14 STRUCTURES)
INSULIN (HUMAN) MUTANT WITH PHE B 24 REPLACED BY GLY (F24G) (NMR, REPRESENTATIVE PLUS 8 STRUCTURES)
NMR STRUCTURE OF THE HUMAN INSULIN-HIS(B16 )
CRYSTAL STRUCTURE OF DESTRIPEPTIDE (B28-B30) INSULIN
INSULIN MUTANT (B1, B10, B16, B27)GLU, DES -B30, NMR, 25 STRUCTURES
INSULIN MUTANT A3 GLY,(B1, B10, B16, B27) GLU, DES-B30, NMR, 19 STRUCTURES
INSULIN MUTANT A8 HIS,(B1, B10, B16, B27) GLU, DES-B30, NMR, 26 STRUCTURES
CRYSTAL STRUCTURE OF AN UNSTABLE INSULIN ANALOG WITH NATIVEACTIVITY.
NON-STANDARD DESIGN OF UNSTABLE INSULIN ANALOGUES WITHENHANCED ACTIVITY
SOLUTION STRUCTURE OF THE MONOMERIC [THR(B27 )->PRO,PRO(B28)->THR] INSULIN MUTANT (PT INSULIN)
NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE- A2-ALA, HIS-B10-ASP, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES
NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE- A2-ALLO-ILE, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES
NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE- A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO- B28-LYS, LYS-B29-PRO, 20 STRUCTURES
NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES
LYS(B28)PRO(B29)-HUMAN INSULIN
MOL_ID: 1; MOLECULE: INSULIN; CHAIN: A, B; ENGINEERED: YES MUTATION: S(B 9)D;
MOL_ID: 1; MOLECULE: INSULIN; CHAIN: A, B; ENGINEERED: YES MUTATION: DES-[PHE(B 25)];
T6 HUMAN INSULIN AT 1.0 A RESOLUTION
DEHYDRATED T6 HUMAN INSULIN AT 100 K
DEHYDRATED T6 HUMAN INSULIN AT 295 K
CRYSTAL STRUCTURE OF ALLO-ILEA2-INSULIN, AN INACTIVE CHIRALANALOGUE: IMPLICATIONS FOR THE MECHANISM OF RECEPTOR
HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH PHENOL
HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH RESORCINOL
HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR
ENHANCING THE ACTIVITY OF INSULIN AT RECEPTOR EDGE: CRYSTALSTRUCTURE AND PHOTO- CROSS-LINKING OF A8 ANALOGUES
NMR STRUCTURE OF HUMAN INSULIN UNDER AMYLOIDOGENICCONDITION, 15 STRUCTURES
MINI-PROINSULIN, TWO CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP, NMR, 20 STRUCTURES
MINI-PROINSULIN, SINGLE CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP AND PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1, NMR, 20 STRUCTURES
SOLUTION STRUCTURE OF HUMAN PROINSULIN C- PEPTIDE
NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES
NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES
NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS- B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS- B29-PRO, 15 STRUCTURES
INSULIN (T3R3) COMPLEX WITH TWO ZINC IONS
INSULIN (T3R3) (PH 6.4, 0.75 M NACL) COMPLEXED WITH TWO ZINC IONS AND TYLENOL ( 4'-HYDROXYACETANILIDE)
INSULIN (T3R3) (PH 5.6, 1.0 M NACL) COMPLEXED WITH TWO ZINC IONS AND TYLENOL ( 4'-HYDROXYACETANILIDE)
CRYSTALLOGRAPHIC AND SOLUTION STUDIES OF N- LITHOCHOLYL INSULIN: A NEW GENERATION OF PROLONGED-ACTING INSULINS.
HUMAN INSULIN TWO DISULFIDE MODEL, NMR, 10 STRUCTURES
STRUCTURAL PROPERTIES OF THE B25TYR-NME- B26PHE INSULIN MUTANT.
STRUCTURE OF INSULIN
HUMAN INSULIN DISULFIDE ISOMER, NMR, 10 STRUCTURES
DIABETES-ASSOCIATED MUTATIONS IN HUMAN INSULIN : CRYSTALSTRUCTURE AND PHOTO-CROSS-LINKING STUDIES OF A-CHAINVARIANT INSULIN WAKAYAMA
STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL
STRUCTURE OF INSULIN
INSULIN, MONOCLINIC CRYSTAL FORM
R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 20 STRUCTURES
INSULINE(1SEC) AND UV LASER EXCITED FLUORESCENCE
INSULINE(60SEC) AND UV LASER EXCITED FLUORESCENCE
NMR STRUCTURE OF HUMAN INSULIN IN 20% ACETIC ACID, ZINC-FREE, 10 STRUCTURES
R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, REFINED AVERAGE STRUCTURE
R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, ' GREEN' SUBSTATE, AVERAGE STRUCTURE
R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, ' RED' SUBSTATE, AVERAGE STRUCTURE
PDBE
Y
PDBE
2006-02-10
REL
SO4
SULFATE ION
HOH
water
DECREASES BLOOD GLUCOSE CONCENTRATION
SO4
122
3
SO4
SO4
122
A
SO4
123
3
SO4
SO4
123
A
SO4
122
3
SO4
SO4
122
C
HOH
2001
4
HOH
HOH
2001
A
HOH
2002
4
HOH
HOH
2002
A
HOH
2003
4
HOH
HOH
2003
A
HOH
2004
4
HOH
HOH
2004
A
HOH
2005
4
HOH
HOH
2005
A
HOH
2006
4
HOH
HOH
2006
A
HOH
2007
4
HOH
HOH
2007
A
HOH
2008
4
HOH
HOH
2008
A
HOH
2009
4
HOH
HOH
2009
A
HOH
2010
4
HOH
HOH
2010
A
HOH
2011
4
HOH
HOH
2011
A
HOH
2012
4
HOH
HOH
2012
A
HOH
2013
4
HOH
HOH
2013
A
HOH
2014
4
HOH
HOH
2014
A
HOH
2015
4
HOH
HOH
2015
A
HOH
2016
4
HOH
HOH
2016
A
HOH
2017
4
HOH
HOH
2017
A
HOH
2018
4
HOH
HOH
2018
A
HOH
2019
4
HOH
HOH
2019
A
HOH
2020
4
HOH
HOH
2020
A
HOH
2021
4
HOH
HOH
2021
A
HOH
2022
4
HOH
HOH
2022
A
HOH
2023
4
HOH
HOH
2023
A
HOH
2001
4
HOH
HOH
2001
B
HOH
2002
4
HOH
HOH
2002
B
HOH
2003
4
HOH
HOH
2003
B
HOH
2004
4
HOH
HOH
2004
B
HOH
2005
4
HOH
HOH
2005
B
HOH
2006
4
HOH
HOH
2006
B
HOH
2007
4
HOH
HOH
2007
B
HOH
2008
4
HOH
HOH
2008
B
HOH
2009
4
HOH
HOH
2009
B
HOH
2010
4
HOH
HOH
2010
B
HOH
2011
4
HOH
HOH
2011
B
HOH
2001
4
HOH
HOH
2001
C
HOH
2002
4
HOH
HOH
2002
C
HOH
2003
4
HOH
HOH
2003
C
HOH
2004
4
HOH
HOH
2004
C
HOH
2005
4
HOH
HOH
2005
C
HOH
2006
4
HOH
HOH
2006
C
HOH
2007
4
HOH
HOH
2007
C
HOH
2008
4
HOH
HOH
2008
C
HOH
2009
4
HOH
HOH
2009
C
HOH
2010
4
HOH
HOH
2010
C
HOH
2011
4
HOH
HOH
2011
C
HOH
2012
4
HOH
HOH
2012
C
HOH
2013
4
HOH
HOH
2013
C
HOH
2014
4
HOH
HOH
2014
C
HOH
2015
4
HOH
HOH
2015
C
HOH
2016
4
HOH
HOH
2016
C
HOH
2017
4
HOH
HOH
2017
C
HOH
2018
4
HOH
HOH
2018
C
HOH
2001
4
HOH
HOH
2001
D
HOH
2002
4
HOH
HOH
2002
D
HOH
2003
4
HOH
HOH
2003
D
HOH
2004
4
HOH
HOH
2004
D
HOH
2005
4
HOH
HOH
2005
D
HOH
2006
4
HOH
HOH
2006
D
HOH
2007
4
HOH
HOH
2007
D
HOH
2008
4
HOH
HOH
2008
D
HOH
2009
4
HOH
HOH
2009
D
HOH
2010
4
HOH
HOH
2010
D
HOH
2011
4
HOH
HOH
2011
D
HOH
2012
4
HOH
HOH
2012
D
HOH
2013
4
HOH
HOH
2013
D
GLY
1
n
1
GLY
1
A
ILE
2
n
2
ILE
2
A
VAL
3
n
3
VAL
3
A
GLU
4
n
4
GLU
4
A
GLN
5
n
5
GLN
5
A
CYS
6
n
6
CYS
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
SER
9
n
9
SER
9
A
ILE
10
n
10
ILE
10
A
CYS
11
n
11
CYS
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
TYR
14
n
14
TYR
14
A
GLN
15
n
15
GLN
15
A
LEU
16
n
16
LEU
16
A
GLU
17
n
17
GLU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
n
1
1
B
VAL
2
n
2
VAL
2
B
ASN
3
n
3
ASN
3
B
GLN
4
n
4
GLN
4
B
HIS
5
n
5
HIS
5
B
LEU
6
n
6
LEU
6
B
CYS
7
n
7
CYS
7
B
GLY
8
n
8
GLY
8
B
SER
9
n
9
SER
9
B
HIS
10
n
10
HIS
10
B
LEU
11
n
11
LEU
11
B
VAL
12
n
12
VAL
12
B
GLU
13
n
13
GLU
13
B
ALA
14
n
14
ALA
14
B
LEU
15
n
15
LEU
15
B
TYR
16
n
16
TYR
16
B
LEU
17
n
17
LEU
17
B
VAL
18
n
18
VAL
18
B
CYS
19
n
19
CYS
19
B
GLY
20
n
20
GLY
20
B
GLU
21
n
21
GLU
21
B
ARG
22
n
22
ARG
22
B
GLY
23
n
23
GLY
23
B
PHE
24
n
24
PHE
24
B
PHE
25
n
25
PHE
25
B
GLY
1
n
1
GLY
1
C
ILE
2
n
2
ILE
2
C
VAL
3
n
3
VAL
3
C
GLU
4
n
4
GLU
4
C
GLN
5
n
5
GLN
5
C
CYS
6
n
6
CYS
6
C
CYS
7
n
7
CYS
7
C
THR
8
n
8
THR
8
C
SER
9
n
9
SER
9
C
ILE
10
n
10
ILE
10
C
CYS
11
n
11
CYS
11
C
SER
12
n
12
SER
12
C
LEU
13
n
13
LEU
13
C
TYR
14
n
14
TYR
14
C
GLN
15
n
15
GLN
15
C
LEU
16
n
16
LEU
16
C
GLU
17
n
17
GLU
17
C
ASN
18
n
18
ASN
18
C
TYR
19
n
19
TYR
19
C
CYS
20
n
20
CYS
20
C
ASN
21
n
21
ASN
21
C
n
1
1
D
VAL
2
n
2
VAL
2
D
ASN
3
n
3
ASN
3
D
GLN
4
n
4
GLN
4
D
HIS
5
n
5
HIS
5
D
LEU
6
n
6
LEU
6
D
CYS
7
n
7
CYS
7
D
GLY
8
n
8
GLY
8
D
SER
9
n
9
SER
9
D
HIS
10
n
10
HIS
10
D
LEU
11
n
11
LEU
11
D
VAL
12
n
12
VAL
12
D
GLU
13
n
13
GLU
13
D
ALA
14
n
14
ALA
14
D
LEU
15
n
15
LEU
15
D
TYR
16
n
16
TYR
16
D
LEU
17
n
17
LEU
17
D
VAL
18
n
18
VAL
18
D
CYS
19
n
19
CYS
19
D
GLY
20
n
20
GLY
20
D
GLU
21
n
21
GLU
21
D
ARG
22
n
22
ARG
22
D
GLY
23
n
23
GLY
23
D
PHE
24
n
24
PHE
24
D
PHE
25
n
25
PHE
25
D
author_and_software_defined_assembly
PQS
4
tetrameric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
SO4
123
F
SO4
1
B
CB
GLU
21
A
B
CB
GLU
21
0
Y
1
B
CB
GLU
21
B
B
CB
GLU
21
0
Y
1
B
CG
GLU
21
A
B
CG
GLU
21
0
Y
1
B
CG
GLU
21
B
B
CG
GLU
21
0
Y
1
B
CD
GLU
21
A
B
CD
GLU
21
0
Y
1
B
CD
GLU
21
B
B
CD
GLU
21
0
Y
1
B
OE1
GLU
21
A
B
OE1
GLU
21
0
Y
1
B
OE1
GLU
21
B
B
OE1
GLU
21
0
Y
1
B
OE2
GLU
21
A
B
OE2
GLU
21
0
Y
1
B
OE2
GLU
21
B
B
OE2
GLU
21
0
Y
1
D
CB
GLU
21
A
D
CB
GLU
21
0
Y
1
D
CB
GLU
21
B
D
CB
GLU
21
0
Y
1
D
CG
GLU
21
A
D
CG
GLU
21
0
Y
1
D
CG
GLU
21
B
D
CG
GLU
21
0
Y
1
D
CD
GLU
21
A
D
CD
GLU
21
0
Y
1
D
CD
GLU
21
B
D
CD
GLU
21
0
Y
1
D
OE1
GLU
21
A
D
OE1
GLU
21
0
Y
1
D
OE1
GLU
21
B
D
OE1
GLU
21
0
Y
1
D
OE2
GLU
21
A
D
OE2
GLU
21
0
Y
1
D
OE2
GLU
21
B
D
OE2
GLU
21
0
Y
1
B
PHE
1
B
PHE
1
1
Y
1
D
PHE
1
D
PHE
1
1
Y
1
A
A
O1
O
SO4
HOH
123
2021
2.02
1
B
B
GLY
PHE
23
24
A
A
-149.78
1
D
D
GLY
PHE
23
24
A
A
-149.95
1
-10.92
1.80
110.60
99.68
B
B
B
N
CA
CB
GLU
GLU
GLU
21
21
21
B
B
B
N
1
-11.49
1.80
110.60
99.11
D
D
D
N
CA
CB
GLU
GLU
GLU
21
21
21
B
B
B
N
1
B
B
CA
CB
GLU
GLU
21
21
0.137
0.022
1.535
1.672
B
B
N
1
B
ARG
22
A
-37.76
-38.09
1
D
GLU
21
B
-69.96
1.04
1
D
ARG
22
A
-39.05
-39.21
19.59
0.38000
0.00000
0.00000
0.15000
0.00000
-0.53000
0.954
0.935
HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. RESIDUES B21-B24 OCCUPY TWO DISTINCT CONFORMATION IN EACH OF THE TWO MOLECULES IN THE ASYMMETRIC UNIT. THIS ENTRY CONTAINS ATOMS WITH ZERO OCCUPANCY FOR WHICH THE B-FACTORS HAVE BEEN FIXED AT 20.00.
0.211
0.172
0.174
1.80
41.13
423
8413
4.800
98.1
4.630
0.068
RANDOM
1
THROUGHOUT
MOLECULAR REPLACEMENT
0.303
0.122
0.80
0.80
1.20
2-ZINC INSULIN
MAXIMUM LIKELIHOOD
BABINET MODEL WITH MASK
1.80
41.13
65
784
15
0
704
0.016
0.021
786
0.001
0.020
662
1.490
1.963
1066
0.818
3.000
1530
7.161
5.000
96
36.886
23.684
38
12.433
15.000
118
8.130
15.000
4
0.085
0.200
110
0.008
0.020
894
0.004
0.020
174
0.216
0.200
157
0.173
0.200
653
0.193
0.200
367
0.084
0.200
405
0.198
0.200
26
0.234
0.200
10
0.179
0.200
26
0.179
0.200
9
1.822
1.500
609
2.232
2.000
756
3.616
3.000
360
4.325
4.500
310
0.2150
0.1450
1.84
36
598
20
1.830
25.000
2CEU
9014
2.000
0.04000
1
31.0000
3.900
98.0
0.07000
1.80
1.83
17.000
1
3.70
94.0
refinement
REFMAC
5.2.0005
data reduction
DENZO
data scaling
SCALEPACK
phasing
AMoRE
INSULIN
Despentapeptide insulin in acetic acid (pH 2)
1
N
N
2
N
N
1
N
N
2
N
N
3
N
N
3
N
N
3
N
N
4
N
N
4
N
N
4
N
N
4
N
N
A
GLY
1
A
GLY
1
HELX_P
A
CYS
7
A
CYS
7
1
1
7
A
SER
12
A
SER
12
HELX_P
A
ASN
18
A
ASN
18
1
2
7
B
CYS
7
B
CYS
7
HELX_P
B
GLY
20
B
GLY
20
1
3
14
C
GLY
1
C
GLY
1
HELX_P
C
CYS
7
C
CYS
7
1
4
7
C
SER
12
C
SER
12
HELX_P
C
ASN
18
C
ASN
18
1
5
7
D
GLY
8
D
GLY
8
HELX_P
D
GLY
20
D
GLY
20
1
6
13
disulf
2.083
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
11
A
SG
CYS
11
1_555
disulf
2.104
A
CYS
7
A
SG
CYS
7
1_555
B
CYS
7
B
SG
CYS
7
1_555
disulf
2.012
A
CYS
20
A
SG
CYS
20
1_555
B
CYS
19
B
SG
CYS
19
1_555
disulf
2.077
C
CYS
6
C
SG
CYS
6
1_555
C
CYS
11
C
SG
CYS
11
1_555
disulf
2.101
C
CYS
7
C
SG
CYS
7
1_555
D
CYS
7
D
SG
CYS
7
1_555
disulf
2.010
C
CYS
20
C
SG
CYS
20
1_555
D
CYS
19
D
SG
CYS
19
1_555
HORMONE
INSULIN, DESPENTAPEPTIDE, ACETIC ACID, PH 2, CARBOHYDRATE METABOLISM, DIABETES MELLITUS, DISEASE MUTATION, GLUCOSE METABOLISM, HORMONE, PHARMACEUTICAL
given
-0.000430
-1.000000
-0.000550
-1.000000
0.000430
0.000370
-0.000370
0.000550
-1.000000
29.09974
29.06617
27.39189
INS_HUMAN
UNP
1
P01308
INS_HUMAN
UNP
2
P01308
90
110
2CEU
1
21
P01308
A
1
1
21
25
49
2CEU
1
25
P01308
B
2
1
25
90
110
2CEU
1
21
P01308
C
1
1
21
25
49
2CEU
1
25
P01308
D
2
1
25
BINDING SITE FOR RESIDUE SO4 A 122
Software
7
BINDING SITE FOR RESIDUE SO4 A 123
Software
3
BINDING SITE FOR RESIDUE SO4 C 122
Software
8
A
GLY
1
A
GLY
1
7
1_555
A
ILE
2
A
ILE
2
7
1_555
A
VAL
3
A
VAL
3
7
1_555
A
GLU
4
A
GLU
4
7
1_555
A
HOH
2023
H
HOH
7
1_555
C
GLY
1
C
GLY
1
7
1_555
C
TYR
19
C
TYR
19
7
1_555
A
HOH
2021
H
HOH
3
1_555
A
HOH
2022
H
HOH
3
1_555
A
HOH
2023
H
HOH
3
1_555
A
GLY
1
A
GLY
1
8
1_555
A
TYR
19
A
TYR
19
8
1_555
A
HOH
2022
H
HOH
8
1_555
C
GLY
1
C
GLY
1
8
1_555
C
ILE
2
C
ILE
2
8
1_555
C
VAL
3
C
VAL
3
8
1_555
C
GLU
4
C
GLU
4
8
1_555
C
HOH
2018
J
HOH
8
1_555
23
I 2 2 2